CleanSpace Holdings Limited has issued a trading update for FY26, projecting a small growth in revenue despite challenging trading conditions and delays in product certification. These delays, along with global economic factors, have hindered market demand, particularly in Australia, the UK, and the USA. However, the company's cash position remains robust at $9.8 million as of April 30, 2026, though a small operating EBITDA loss is anticipated. In contrast, markets in France and the Nordics have shown resilience. The company is set to benefit from increasing regulatory requirements for respiratory protection, which creates a favorable growth environment for its products. CleanSpace plans to launch a new respirator product shortly and remains committed to its growth strategy, with further updates to be provided with the full-year results in August 2026.
Key Points
CleanSpace Holdings Limited provides a trading update for FY26.
The company expects full-year revenue growth in low single digits due to challenging conditions.
Revenue impacted by delays in product certification and macroeconomic conditions.
CleanSpace's cash balance remains strong at $9.8 million as of 30 April 2026.
Operating EBITDA is expected to be a small loss for the full year.
Delays in certification have affected revenue timing in Australia, the UK, and the USA.
Despite challenges, France and the Nordics show resilience.
Strengthening compliance requirements in the respiratory protection sector offer growth opportunities.
CleanSpace is preparing to launch a new respirator product soon.
The Board is focused on the company's growth strategy and will update further with FY26 results in August 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.